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CAlternative Smoking Cessation Aids: A Meta-analysis of Randomized
Controlled Trials
Tahiri M., Mottillo S., Joseph L.. Am J Med 2012;125:576-84.
Conclusion: Acupuncture and hypnotherapy both appear useful in
smoking cessation. Additional evidence is needed to determine whether
alternative interventions are as efficacious as pharmacologic therapies.
Summary: Smoking is estimated to cost the U.S. economy $210
billion each year and is the most preventable cause of morbidity and
mortality in North America (Chandler MA, Renard SI, Chest 2010;137:
428-35; Rehm J et al, J Stud Alcohol Drugs 2007;68:886-95). There are 51
million smokers in North America, and each year half of them attempt to
quit at least for 1 day. (MMWR 2009;58:1227-32). Less than 50% of
smokers attempting smoking cessation use pharmacologic aids such as
nicotine replacement therapy, bupropion, or varenicline. Alternative meth-
ods of smoking cessation include acupuncture, stimulating specific acupoints
on the ear, hypnotherapy, inducing an altered state of consciousness broadly
enabling adherence to smoking cessation, and aversion smoking therapy
consisting of rapidly taking a large number of puffs in a short period of time.
Between 30% and 40% of smokers have reported an interest in trying
acupuncture and hypnotherapy, but these alternative aids are costly, with the
total price of each therapy ranging from $400 to $1000 (Sood A et al,
Nicotine Tob Res 2006;8:767-71). A number of randomized controlled
trials have examined the efficacy of alternative smoking cessation aids. The
objective of this study was to carry out a systematic review and meta-analysis
to determine the efficacy of all alternative smoking cessation aids. The
authors preformed a random affects meta-analysis of randomized controlled
trials evaluating alternative smoking cessation aids. They systematically
searched the Cochrane Library, EMBASE, Medline, and PsycINFO data-
bases through December 2010. They included trials that reported cessation
outcomes as point prevalence or continuance abstinence at 6 or 12 months.
The authors identified 14 relevant trials: six trials investigated acupuncture
(823 patients), four trials investigated hypnotherapy (273 patients), and four
investigated aversive smoking (99 patients). Estimated mean treatment
affects were acupuncture (odds ratio [OR], 3.53; 95% confidence interval
[CI], 1.03-12.07) hypnotherapy (OR, 4.55; 95% CI, 0.98-21.01), and
aversive smoking (OR, 4.26; 95%, 1.26-14.38).
Comment: The report concludes there is reasonable evidence that
acupuncture and hypnotherapy are both useful as alternative stop smoking
aids. The authors also feel the evidence is sufficiently strong that physicians
should promote the use of acupuncture and hypnotherapy as alternative
smoking cessation aids in patients who wish to quit smoking. The evidence
regarding aversive smoking is somewhat old, and therefore, additional more
recent studies are needed to potentially recommend this intervention to
physicians. Finally, additional data are also needed to determine the relative
effectiveness of pharmacologic vs alternative smoking aids and their combi-
nation use to facilitate smoking cessation.
Aspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini C., Agnelli G., Schenone A., et al; WARFASA Investigators. N
Engl J Med 2012;366:1959-67.
Conclusion: In patients with unprovoked venous thromboembolism
(VTE), who discontinue anticoagulation treatment, aspirin reduces risk of
VTE recurrence without an increased risk of major bleeding.
Summary: Patients with unprovoked VTE who discontinue anticoag-
ulation therapy with vitamin K antagonists have about a 20% incidence of
VTE recurrence within 2 years (Schulman S, N Engl J Med 1995;332:
1661-5; and Prandoni P, Ann Intern Med 1996;125:1-7). In studies of
primary prevention of VTE, aspirin has been associated with a risk reduction
ranging from 20% to 50% (Antiplatelet Trialists’ Collaborative, BMJ 1994;
308:235-46). One small randomized trial of 39 patients has previously
suggested a benefit of antiplatelet agents in reducing recurrence of venous
thrombosis (Steele P, Lancet 1980;2:1328-9). The goal of this study, the
aspirin for the prevention of recurrent VTE (the Warfarin and Aspirin study
[WARFASA]), was to assess the potential benefit of aspirin to prevent
recurrence of VTE after standard vitamin K antagonist therapy. This was a
multicenter investigator-initiated double-blind study. Patients included in
the study had a first-ever unprovoked VTE and had completed 6 to 18
months of vitamin K antagonist therapy after diagnosis. They were then
randomly assigned to aspirin (100 mg daily) or placebo for 2 years. There
was an option to extend study treatment. Primary efficacy outcome was
recurrence of VTE. The primary safety outcome was major bleeding. VTE
recurred in 28 of 205 patients who received aspirin and in 43 of 197 patients
who received placebo (6.6% vs 11.2% per year; hazard ratio, 0.58: 95%
t
aonfidence interval, 0.36-0.93; median study period, 24.6 months). With a
edian treatment of 23.9 months, 23 patients taking aspirin and 39 taking
lacebo had VTE recurrence (5.9% vs 11.0% per year: hazard ratio, 0.55;
5% confidence interval, 0.33-0.92). One major bleeding episode occurred
n each group, and adverse events were similar in the aspirin-treated and
lacebo-treated groups.
Comment: There is currently intense interest in the use of aspirin to
revent VTE. Patients at low to moderate risk of bleeding, based on the best
vailable evidence, derive the greatest overall benefit from extending anti-
oagulation therapy. The use of aspirin to reduce VTE events, however, is
articularly intriguing in that aspirin may be applicable to patients at higher
isk of bleeding and requires less intensive monitoring than use of vitamin K
ntagonists. The Aspirin to Prevent Recurrent of VTE (ASPIRE) study is
ngoing and has recruited, at the time of publication of this report, 822
atients with a first unprovoked VTE event. Patients are being randomly
ssigned to aspirin (100 mg daily) or placebo and are under follow-up for a
rst recurrence of symptomatic and objectively confirmed, nonfatal or fatal,
eep venous thromboembolism using an intention-to-treat analysis ap-
roach. This study is expected to report results in 2012. If this study
onfirms the current conclusion in the report abstracted here, we may be on
he verge of a paradigm shift in how patients with unprovoked VTE are
reated long-term.
linical Prediction Rule to Estimate the Absolute 3-Year Risk of Major
ardiovascular Events After Carotid Endarterectomy
an Lammeren GW., Catanzariti LM., Peelen LM., et al. Stroke 2012;43:
273-8.
Conclusion: Clinical risk models can be developed to predict major
dverse cardiovascular events (MACE) in the first 3 years after carotid
ndarterectomy (CEA).
Summary:CEA is one of themost frequently performed procedures by
ascular surgeons. Reducing adverse events in patients undergoing CEA has
oncentrated on the perioperative period. However, patients with carotid
therosclerosis have systemic atherosclerosis as well, and efforts should be
ade to reduce MACE in the years after CEA. The authors contend
nitiation of treatment and aggressiveness in treatment to reduce cardiovas-
ular events after CEA should be determined by the absolute level of risk of
ardiovascular events in this patient group. They note that prediction of
econdary cardiovascular events after CEA is an area that has not been
elatively well explored. In this report, they sought to develop a clinical score
hart to stratify patients for absolute risk of MACE after CEA. The predic-
ion model was developed in a consecutive cohort of 1138 patients who
nderwent a CEA between 2002 and 2009. The primary end point was
ACE (myocardial infarction, stroke, and cardiovascular death). Potential
redictors (n  14) were entered in to a Cox proportional hazard model.
ackward stepwise regression and internal validation with boot strapping
echniques was used to correct for over-fitting. A score chart was constructed
n an effort to provide an applicable clinical tool. The chart divides patients
nto four risk groups. The performance of the model was assessed in terms of
isk stratification, discrimination, and calibration. In the cohort studied,
uring a mean follow-up of 2.28 0.95 years, there were 148 MACE. This
orresponded to a cumulative incidence of 13%. Clinical predictors in the
nal model included were age, history of peripheral vascular disease, history
f coronary disease, systolic blood pressure, smoking, clinical presentation,
se of antihypertensive drugs, serum creatinine levels, and presence of a
50% contralateral internal carotid artery stenosis. Discrimination of the
nal model by C statistic was 0.69 (0.64-0.73). Calibrations showed a good
verall fit (Gronnesby Borgan, P .39). The observed incidence of MACE
n the four risk groups was 6%, 9%, 19%, and 35%, respectively, suggesting
verall good risk stratification.
Comment: It is difficult to know what to do with this sort of informa-
ion. All of the patients, included in this study that were stratified for
dditional MACE during the subsequent 3 years after CEA had, in fact,
ndergone CEA. Therefore, all the patients had serious atherosclerotic
isease. Even if one can stratify risk of MACE in the subsequent 3-year
eriod, why would one not offer “less-risk” patients the same level of
ggressive treatment as “higher-risk” patients? One can certainly argue that
ll patients who have undergone CEA, regardless of predicted further risk of
ACE, should be offered maximal treatment of their atherosclerotic risk
actors. The most important aspect of this report may not be the risk
rediction score but that it highlights the fact that subsequent MACE after
EA are frequent. All patients with any form of atherosclerosis that has led
o surgical intervention deserve maximal medical management of their
therosclerotic risk factors.
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